UCB : Bimekizumab enjeu principal de 2021
>2021 : année de croissance top et bottom line - 2020 aura été une année dynamique pour UCB au niveau de la croissance de ses revenus (+8% à changes constants). Même si le tassement de la profitabilité (marge d’EBITDA à 26,9% vs 29,1%) a conduit à un BPA Core quasi stable vs 2019 (-2% à cc), au final UCB fait mieux que ses attentes 2020. Surtout UCB propose des objectifs 2021 attractifs et supérieurs au consensus avec notamment des revenus à 5.45-5.65 Md€ et un BPA Co...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.